Share this article:
Interview with Life Science Angel Investor Scott Fishman
Scott Fishman is the President & CEO Ethos LifeScience Advisors, Envisage. Scott has more than three decades’ experience as a strategic advisor to the medical technology and pharmaceutical industries. As CEO of the firm he started in 1989, Scott directed the evolution of Research by Design (RBD) from a bedroom startup to one of the most successful and prominent firms in the medical information industry.
He has counseled virtually every major pharmaceutical company and a wide spectrum of biotechnology and medical device companies. Following the sale of RBD to a global holding company, Scott founded Ethos LifeScience Advisors in 2006 and Envisage in 2014. Ethos and Envisage provide commercial guidance for entrepreneurs, startups and new product developers, informing market development and investment decisions with definitive analysis of the clinical and commercial value of new technologies.
Fishman is co-author of Preserving the Promise: Improving the Culture of Biotech Investment, which examines the early biotech funding ecosystem and proposes solutions to facilitate translation of important discoveries from the laboratory to the clinic. He is an active Angel investor with Robin Hood Ventures and sits on the Therapeutics, Devices and Diagnostics investment review committee for Ben Franklin Technology Partners.
He is also a faculty member in the Strategic Management department at Temple University and in Philadelphia University’s MBA program. At the University of Pennsylvania’s Wharton School, he co-created and served as Program Executive for the Commercialization Acceleration Program (CAP), a consultancy that provides experiential education for students while supporting the development and funding of technology-based start-up companies.
Fishman is an in-demand speaker who has presented on biotechnology innovation at such venues as Harvard’s i-Lab, the Yale School of Management, the University of Pennsylvania School of Medicine and Wharton School, Princeton’s eLab, and the National Science Foundation’s annual SBIR meeting. He holds an undergraduate degree in English Literature from the University of Pennsylvania and a master’s degree in Advertising from the University of Texas.
The author of this article was reported by Ariel Kramer for Biotech Buzz. Read the original article here.
For a limited time, you can download a free chapter on “Porter’s Five Forces and the Market for Angel Capital” from Preserving the Promise.
This book is now available on ScienceDirect. Need it in print? Visit the Elsevier Store and save up to 30% by using promo code STC317 at checkout.
Biomedicine & Biochemistry
The disciplines of biomedicine and biochemistry impact the lives of millions of people every day. Research in these areas has led to practical applications in cardiology, cancer treatment, respiratory medicine, drug development, and more. Interdisciplinary fields of study, including neuroscience, chemical engineering, nanotechnology, and psychology come together in this research to yield significant new discoveries. Elsevier’s biomedicine and biochemistry content spans a wide range of subject matter in various forms, including journals, books, eBooks, and online information services, enabling students, researchers, and clinicians to advance these fields. Learn more about our Biomedical and Biochemistry books here.